AIM: To investigate the efficacy of intravitreal injection of Conbercept in the treatment of diabetic macular edema(DME).

METHODS: Totally 95 patients(95 eyes)with diabetic macular edema treated in our hospital from January 2014 to December 2016 were retrospectively analyzed, and 42 cases received Ranibizumab intravitreal injection were included into control group, 53 cases treated with conbercept intravitreal injection were included into observation group. The changes of preoperative and postoperative follow up visual acuity and macular foveal thickness in the two groups were observed. The repeated medication, complications and medical expenses were also compared.

RESULTS: The preoperative best corrected visual acuity between groups showed no difference(P>0.01). The postoperative best corrected visual acuity between groups showed distinct difference(F=105.326, P<0.01; F=86.365, P<0.01). At 3mo after the operation, visual acuity of two groups sharply improved, a significant difference was shown within the groups(P<0.05), but held no obvious difference between groups(P>0.05). At 6mo after operation, the observation group's visual acuity was evidently higher than that at 3mo(P<0.05). The visual acuity at postoperatively 6mo of the observation group was significantly higher than that of the control group, the difference between groups was statistically marked(P<0.01). The control group's visual acuity at postoperative 3 and 6mo showed no marked difference(P>0.05). The overall changes of foveal thickness between two groups showed a significant difference(F=86.365, P<0.01; F=84.235, P<0.01). The foveal thickness reduced obviously during the postoperative 1, 3 and 6mo of followed up, which showed remarkable difference within groups(P<0.05)but no difference between groups(P>0.05). The repeated medication of observation group during the postoperative 1, 3 and 6mo of followed up was evidently less than that of the control group, the difference between groups was significant(P<0.05). There was no statistical difference between groups in complications after operation(P>0.05). The average medical cost of the observation group was obviously less than that of the control group, and the difference between the two groups was evident(P<0.01).

CONCLUSION: Intravitreal injection of conbercept in the treatment of diabetic macular edema can effectively enhance vision and relieve macular edema, as well as shows lasting efficacy, low cost and high safety.